Corning Incorporated has entered into an agreement with BioLamina to manufacture and package the Recombinant Laminin-521 (rLaminin-521) pluripotent stem-cell and neural stem-cell growth matrix.
“As cell-culture and cell-therapy technologies progress, it is increasingly important to offer today’s researchers more powerful and reliable culture systems,” said Kristian Tryggvason, Ph.D., CEO, BioLamina. “Through this agreement with Corning, and the resulting global availability of rLaminin-521, we enable more scientists to have access to this tool for aiding their stem-cell cultivation.”
“Scalable animal-free cell culture surfaces are becoming essential for the translation from basic to applied research, along with consistent and dependable culture vessels and media. rLaminin-521 is an important addition to Corning’s full solution approach and to our expanding cell-culture portfolio of advanced surfaces,” said Lynsey Willetts, Ph.D., director of Advanced Cell Culture, Corning Life Sciences. “By working with BioLamina, Corning now offers researchers who work with pluripotent and neural stem cells a more comprehensive and scalable cell culture solution – from research to production.”
